News & Updates

Show Multimedia Only

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026 by

In the first-line treatment of acquired haemophilia A (AHA), the use of an intravenous (IV) pulse-dose immunosuppression regimen that combines cyclophosphamide, dexamethasone, and rituximab appears to result in faster remission and improved survival compared with traditional oral sequential prednisone-based regimens, according to a study.

Upfront immunosuppression regimen improves survival in acquired haemophilia A

05 Jul 2026

Novel oral small-molecule PCSK9 inhibitor shows promise in hypercholesterolemia

04 Jul 2026

In the treatment of hypercholesterolemia, the investigational oral small-molecule PCSK9 inhibitor laroprovstat appears well tolerated and may help reduce low-density lipoprotein cholesterol (LDL-C) levels when used in combination with rosuvastatin, according to a phase I study.

Novel oral small-molecule PCSK9 inhibitor shows promise in hypercholesterolemia

04 Jul 2026

CCB outperforms beta-blocker for managing hypertension in HFpEF

03 Jul 2026 by

The oral dihydropyridine calcium channel blocker (CCB) amlodipine appears more beneficial than the beta-blocker metoprolol for managing hypertension in patients with heart failure with preserved ejection fraction (HFpEF), with greater effects on blood pressure (BP) control and exercise capacity, as shown in a randomized crossover trial.

CCB outperforms beta-blocker for managing hypertension in HFpEF

03 Jul 2026

How does baricitinib compare in RA patients at risk of VTE?

03 Jul 2026 by

Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.

How does baricitinib compare in RA patients at risk of VTE?

03 Jul 2026

Novel extended-release tablet superior to febuxostat at reducing SUA levels

03 Jul 2026 by

An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.

Novel extended-release tablet superior to febuxostat at reducing SUA levels

03 Jul 2026

$Substance use, poverty, race predictive of orbital, facial fractures$

Substance use, poverty, race predictive of orbital, facial fractures

03 Jul 2026

Social determinants of health (SDOH) are significantly associated with maxillofacial trauma, suggests a US study. These SDOH factors include substance use, unhoused status, and poverty, among others

Substance use, poverty, race predictive of orbital, facial fractures

03 Jul 2026

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

03 Jul 2026 by

In the phase III RISE UP trial, mitapivat—approved for pyruvate kinase (PK) deficiency and thalassemia—shows a strong antihaemolytic effect in individuals with sickle cell disease (SCD).

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

03 Jul 2026

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

02 Jul 2026 by

For children and young adults with acute myeloid leukaemia (AML) and measurable residual disease (MRD) negativity, proceeding to allogeneic hematopoietic stem cell transplant (HSCT) after two rounds of chemotherapy is as effective as completing a third cycle prior to HSCT, yielding similar transplant outcomes, according to a multicentre retrospective study.

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

02 Jul 2026

Intravitreal anti–VEGF injections tied to cataract development, surgery

02 Jul 2026

Long-term treatment with intravitreal antivascular endothelial growth factor (anti-VEGF) appears to elevate the risk of developing cataract that requires surgical intervention, reports a study.

Intravitreal anti–VEGF injections tied to cataract development, surgery

02 Jul 2026

Rucaparib extends time to subsequent therapy in advanced ovarian cancer

02 Jul 2026 by

In patients with newly diagnosed advanced ovarian cancer, treatment with rucaparib delays the median time to first and second subsequent anticancer therapy for almost 1 year relative to placebo, according to a study presented at ESMO Gyn 2026.

Rucaparib extends time to subsequent therapy in advanced ovarian cancer

02 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Upfront immunosuppression regimen improves survival in acquired haemophilia A

Upfront immunosuppression regimen improves survival in acquired haemophilia A

Novel oral small-molecule PCSK9 inhibitor shows promise in hypercholesterolemia

Novel oral small-molecule PCSK9 inhibitor shows promise in hypercholesterolemia

CCB outperforms beta-blocker for managing hypertension in HFpEF

CCB outperforms beta-blocker for managing hypertension in HFpEF

How does baricitinib compare in RA patients at risk of VTE?

How does baricitinib compare in RA patients at risk of VTE?

Novel extended-release tablet superior to febuxostat at reducing SUA levels

Novel extended-release tablet superior to febuxostat at reducing SUA levels

Substance use, poverty, race predictive of orbital, facial fractures

Substance use, poverty, race predictive of orbital, facial fractures

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

Mitapivat RISEs UP as a potential Tx alternative for sickle cell disease

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

Two chemo cycles sufficient prior to HSCT in MRD-negative acute myeloid leukaemia

Intravitreal anti–VEGF injections tied to cataract development, surgery

Intravitreal anti–VEGF injections tied to cataract development, surgery

Rucaparib extends time to subsequent therapy in advanced ovarian cancer

Rucaparib extends time to subsequent therapy in advanced ovarian cancer